Osteal Therapeutics Stock

ostealtx.comHealthcare / BioTech & PharmaFounded: 2013

Osteal Therapeutics, founded in 2013, is a biopharmaceutical company that striving to develop novel musculoskeletal therapeutics with the goal of treating infections that affect orthopedic systems. The company has developed a treatment called VT-X7, which is for periprosthetic joint infection (PJI), a rare complication that can occur during joint replacement surgeries. The treatment aims to target affected tissues directly with antibiotics and is intended to be more effective than traditional PJI treatments. Osteal Therapeutics is headquartered in Dallas, Texas.

Register To Buy and Sell Shares

For more details on financing and valuation for Osteal Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Osteal Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Osteal Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

David Thompson
Chief Executive Officer & President
Jude Paganelli
Co-Founder & Chief Technology Officer
Brian de Beaubien MD
Co-Founder & Chief Medical Officer
Todd Saunders
Vice President of Marketing
Joan Ceasar
Vice President of Quality Assurance
Cam Hutton
Vice President of Research and Development
Kathy Burke
Vice President of Market Access
Trey Putnam
Chief Operating Officer

Board Members

Biren Mehta
Johnson & Johnson Innovation - JJDC
David Cash
Medvest Capital
Robert Luo
HM Capital
Steven Sands
Asteroid Partners

Osteal Therapeutics’ stock FAQs

plusminus

Can you buy Osteal Therapeutics’ stock?

Osteal Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy Osteal Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus

Can you sell Osteal Therapeutics’ stock?

Yes, you can sell stock of a private company like Osteal Therapeutics. Forge can help you sell your Osteal Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus

What is Osteal Therapeutics’ stock price?

Osteal Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Osteal Therapeutics’ private market stock price with Forge Data.
plusminus

What is Osteal Therapeutics’ stock ticker symbol?

Osteal Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Osteal Therapeutics Closes $50M Series D Financing to Support Approval and Commercial Launch of Lead Candidate

In a series D funding round led by Zimmer Biomet, Osteal Therapeutics raised $50 million.

Osteal Therapeutics Closes $23M Series C Financing

Osteal Therapeutics, Inc. (“Osteal”), a clinical-stage biopharmaceutical company developing a new category of combination therapies for orthopedic infections, announced today the completion of an oversubscribed $23 million Series C equity financing.
Updated on: Jun 21, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.